Summary of MediWound Conference Call Company Overview - **Company**: MediWound - **Key Products**: NexoBrid and EscharEx - **Market Focus**: Wound care, specifically for severe burns and chronic wounds - **Current Financials**: $54 million in cash, with a revenue-generating business in NexoBrid Industry Insights - **Total Addressable Market (TAM)**: - Severe burns in the U.S. is approximately $300 million [2] - Chronic wounds applicable to EscharEx are around 4 million, indicating a much larger market potential [5] Product Development and Clinical Trials - **NexoBrid**: - Approved for eschar removal in severe burns, with a focus on mass casualty events [5][6] - Manufacturing capacity is set to expand sixfold, with inspections by EMA and FDA planned [7][8] - **EscharEx**: - Undergoing Phase 3 trials for venous leg ulcers (VLUs) and Phase 2 for diabetic foot ulcers (DFUs) [6][9] - Expected to file for approval in 2027, with potential market entry in 2028 [11] Clinical Efficacy - **Debridement Efficiency**: - EscharEx shows 63% complete debridement within two weeks compared to 0% for SANTYL, a competitor [20] - Average time to wound bed preparation is significantly shorter with EscharEx (48.4 days) compared to SANTYL (76 days) [20] - **Market Positioning**: - EscharEx aims to capture a significant share of the chronic wound market, with projected peak sales in the U.S. reaching $831 million from a $2.5 billion TAM [20][21] Strategic Partnerships and Funding - **Collaborations**: - Partnerships with global companies to validate technology and support clinical studies [2][27] - **Government Funding**: - Initial funding for NexoBrid development has come from U.S. government sources, including the Department of Defense [5] Future Projections - **Revenue Growth**: - Projected revenue for this year is $24-$26 million, increasing to $32-$35 million next year [11][12] - Potential for higher margins (up to 65%) with increased manufacturing capacity [10] - **Market Expansion**: - Plans to expand into additional markets, including Europe and Japan, post-approval [8][10] Risks and Considerations - **Regulatory Approval**: - Success hinges on timely inspections and approvals from EMA and FDA [8][9] - **Market Competition**: - SANTYL remains a significant competitor, with established market presence and sales of over $370 million annually [18] Conclusion MediWound is positioned for significant growth in the wound care market, with promising clinical data for EscharEx and a solid foundation with NexoBrid. The company is actively expanding its manufacturing capabilities and exploring strategic partnerships to enhance its market presence.

MediWound FY Conference Summary Company Overview - **Company**: MediWound (NasdaqGM:MDWD) - **Industry**: Biologics and Wound Care - **Key Products**: NexoBrid (approved drug), EscharEx (Phase III asset) [2][3] Core Points and Arguments NexoBrid - **Description**: FDA-approved drug for burn treatment, commercialized in major markets including the U.S., Europe, and Japan [2] - **Efficacy**: Removes burn eschar within 4 hours, spares healthy tissue, and significantly reduces the need for surgery [2][5] - **Market Validation**: Generates revenue and is profitable, with a strong balance sheet supported by a recent $30 million capital raise [3][11] - **Manufacturing Expansion**: Recently expanded manufacturing facility to meet global demand, expected to alleviate current supply constraints by mid-2026 [10][11] EscharEx - **Description**: Currently in Phase III trials for chronic wounds, targeting a $2.5 billion U.S. debridement market [3][7] - **Efficacy**: Acts in days rather than weeks, with a strong safety profile demonstrated in Phase II studies [14][19] - **Market Opportunity**: Estimated peak sales revenue of approximately $831 million across venous leg ulcers and diabetic foot ulcers [19] - **Clinical Trials**: Interim Phase III readout expected by late 2026, with a focus on complete debridement and facilitating wound closure [9][16] Financial Position - **Cash Reserves**: $54 million in cash, no debt, allowing for strategic execution without near-term financing pressure [11] - **Government Collaboration**: Long-standing collaboration with the U.S. government, which funds a significant portion of operations [11][23] Additional Important Content - **Regulatory Inspections**: New manufacturing facility requires regulatory inspections for product stability before market deployment, expected to begin mid-2026 [21][30] - **BARDA Contract**: Anticipated conclusion of the BARDA agreement in Q1 2026, which will support stockpiling and development of room temperature stable indications [23][24] - **Market Dynamics**: Current enzymatic debridement options are limited, with EscharEx positioned to capture market share from surgical procedures [19][20] - **Clinical Trial Design**: The Phase III trial involves 216 patients across approximately 40 sites in the U.S. and Europe, with a focus on maintaining high statistical power for success [16][32] Conclusion - MediWound is positioned for significant growth with its validated technology in severe burns and a promising pipeline in chronic wound care. The upcoming regulatory approvals, manufacturing expansions, and clinical trial results are critical for future value creation [20]

Financial Data and Key Metrics Changes - For Q4 2024, the company reported revenue of $5.8 million, an increase from $5.3 million in Q4 2023 [24] - Gross profit for Q4 2024 was $0.9 million with a gross margin of 15.5%, up from $0.7 million and a 13.5% margin in Q4 2023 [25] - The full year revenue for 2024 was $20.2 million, compared to $18.7 million in 2023, driven by higher revenue from Vericel and a new contract with the U.S. Department of Defense [27] - The net loss for the year was $30.2 million or $3.03 per share, compared to $6.7 million or $0.75 per share in the prior year [29] Business Line Data and Key Metrics Changes - EscharEx is in Phase 3 trials with a peak sales potential estimated at $725 million for its primary indications [9] - NexoBrid generated annual revenue of $20.2 million in 2024, with projected revenue of $24 million in 2025 [18] - The company anticipates a Phase 2/3 clinical trial for diabetic foot ulcers (DFU) to begin in 2026 [15] Market Data and Key Metrics Changes - NexoBrid is now available in over 90 burn centers in Europe and has been adopted by over 400 medical facilities in Japan [19] - The new Medicare LCD policy, effective April 13, 2025, will require full wound debridement before covering cellular- and tissue-based products, which positions EscharEx favorably [55] Company Strategy and Development Direction - The company aims to strengthen its position through clinical development, commercial expansion, and strategic partnerships [6] - MediWound is focusing on delivering meaningful improvements in patient care while expanding market adoption [32] - The company has secured €16.5 million in funding from the European Innovation Council to accelerate EscharEx development for diabetic foot ulcers [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategic partnerships and clinical trial designs, emphasizing a focus on quality over speed in patient recruitment [68] - The company expects to achieve regulatory approvals for NexoBrid in Europe and the U.S. by mid-2026 [46] Other Important Information - The company completed the construction of a new GMP manufacturing facility, expected to reach full operational capacity by late 2025 [22] - A strategic $25 million PIPE financing round was completed, enhancing the company's financial position [23] Q&A Session Summary Question: What are the roles of the wound care collaborators in the VALUE study? - Collaborators will provide standardized products and training to minimize variability and optimize outcomes [37][38] Question: Will the DFU study be global and how will it compare to the VLU study? - The DFU study will be similar to the VLU study, pending regulatory approval [41] Question: What is the expected timeline for regulatory approvals for NexoBrid? - Expected approvals are in early 2026 for Europe and mid-2026 for the U.S. [46] Question: How does the new Medicare LCD policy impact MediWound? - The policy emphasizes documentation for wound debridement, which aligns with EscharEx's capabilities [55][56] Question: How does EscharEx compare to SANTYL? - EscharEx has shown superior results in key clinical endpoints compared to SANTYL [64] Question: What is the status of the collaboration with BARDA for a U.S. facility? - The company is in the planning stages for a U.S. facility, with a timeline of approximately three years for completion [73]